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Abstract Electrochemotherapy (ECT) is a novel treatment
for recurrent or in-transit unresectable melanoma metastases
based on the administration of anti-neoplastic drugs fol-
lowed by cancer cell electroporation. Whether ECT can also
induce anti-tumour immunity is unclear. We addressed this
issue investigating the presence of dendritic cells (DCs) in
the inflammatory infiltrate of ECT-treated lesions. Biopsies
from melanoma patients (n = 9) were taken before ECT
(T0), at d7 and d14 after treatment and studied by immu-
nofluorescence with DCs-related antibodies. Epidermal
Langerin? Langerhans cells (LCs) were the most repre-
sented subset before treatment. ECT induced a significant
reduction in epidermal LCs number at d7 (p \ 0.001), while
they were completely replaced at d14. Similarly, the few LCs
observed intermingled with metastatic melanoma cells at T0
decreased after treatment (p \ 0.001), suggesting an ECT-
induced activation of LCs. Consistently, at d1 after ECT
(n = 3 patients), LCs were found to express CCR7, which
mediates LCs migration to regional lymph nodes, and CD83,
the typical DCs maturation marker. In contrast, plasmacytoid
DCs (pDCs) were not present at T0, but significantly
increased after ECT both in melanoma metastasis
(p \ 0.001) and perilesionally (p \ 0.05). Similarly, CD1c?
dermal DCs (dDCs), observed in low number before ECT,
strongly increased at d7 and even more at d14 (p \ 0.05 and
p \ 0.001, respectively). Notably, some dDCs expressed
CD83. These data suggest that ECT promotes LCs migration
from the tumour to draining lymph nodes and pDCs and
dDCs recruitment at the site of the lesion. These findings may
help to design new strategies of in situ DCs vaccination in
cancer patients.
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Introduction
Electrochemotherapy (ECT) is emerging as a highly effective
local treatment for skin metastasis of human cancers and it is
particularly used for recurrent or in-transit unresectable mel-
anoma metastases [1, 2]. ECT treatment is based on the
administration of anti-neoplastic drugs, such as bleomycin or
cisplatin, followed by the electroporation of the lesions [3].
The electric currents, increasing cell membrane permeability,
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promote the intracellular concentration of the drug and
increase its cytotoxicity [4]. Although the overall objective
response rate is high, approximately 80–90 % [1], it is gen-
erally accepted that ECT has only local effects, therefore it is
currently used as a palliative treatment. However, some
findings support the view that ECT can also induce anticancer
immunity, especially in melanoma which is considered the
most immunogenic tumours [5, 6]. Particularly, ECT treat-
ment combined with IL-2 administration induced specific
CTL responses [5]. Indeed, melanoma expresses several well
known tumour associated antigens (TAA) [6, 7], although
most of them are self antigens to which a considerable
immunological tolerance is maintained [8]. ECT induces a
massive cancer cell death, with the release of several TAA
which might become available for immunity activation. For
these reasons, melanoma represents an ideal model to study
the possible involvement of the immune system after ECT.
Dendritic cells (DCs) are the professional antigen pre-
senting cells with the unique ability to initiate primary
immune responses and are supposed to play a key role in
cancer immunology [9, 10]. DCs orchestrate the immune
responses and are capable to generate immunity or, in
contrast, tolerance towards TAA primarily depending on
their maturation state and on the tumour microenvironment
[7, 8]. However, properly stimulated DCs represent a pow-
erful tool to overcome the immune tolerance conditions
towards melanoma TAA and generate potent anti-cancer
immune responses [8]. Indeed, DC-based immunotherapy
has been reported to induce regression of metastatic lesions
in melanoma patients [11].
The possibility to exploit the ECT technology aiming to
extend the local results to an effective systemic treatment is
an intriguing challenge. Thus, the application of ECT fol-
lowed by DC-based immunotherapy would be a reasonable
approach to reach this goal. The release of TAA after ECT-
induced melanoma metastasis destruction could represent
an ideal source of antigens for local DCs that, upon
migration to the draining lymph node (LN), might present
these antigens to specific cytotoxic T cells.
In this study, we analyzed the presence of the different
DC subsets at the site of the lesion, before and after ECT
treatment, in order to investigate the feasibility of DC-
based immunotherapy following ECT treatment.
Methods
Patients and human tissues
Melanoma patients (n = 9) with histological confirmed
skin metastasis undergoing ECT with bleomycin were
enrolled in the study after obtaining informed written con-
sents. The study was conducted according to Declaration of
Helsinki Principles and Local Institutional Ethics Com-
mittee approved all described analyses.
Cutaneous and/or subcutaneous melanoma metastases
were treated using CliniporatorTM device (IGEA Ltd, Mo-
dena, Italy). Electric pulses were applied with the appropri-
ate type of electrodes (IGEA Ltd): by needle electrodes
(Type II and III) to deeper seated metastasis and by plate
electrodes (Type I) to superficial metastasis. The needle
electrodes were chosen based on metastasis dimensions:
Type II for small nodules (less than 1 cm) and Type III for
large nodules (more than 1 cm). All the lesions treated were
smaller than 3 cm in diameter. Bleomycin was administered
intravenously (15,000 UI/m2 body surface area) in a time
frame of 60 s. The electrical pulses (variable amplitude with
1–5,000 Hz delivery frequencies) were applied to the
metastasis in a time window between 8 and 28 min after
bleomycin infusion to obtain the optimal response utilizing
the most appropriate drug concentrations in tissues,
according to previous standardized procedure [1, 4].
Skin biopsies were obtained before ECT, indicated as T0,
and at seven and 14 days after treatment, indicated as d7 and
d14 post, from different lesions. In the last three patients
enrolled in the study we obtained additional samples after
24 h, indicated as d1 post. Specimens were embedded in
OCT-like medium (Killik; Bio-Optika, Milan, Italy), snap-
frozen in liquid nitrogen and stored at -80 C. Cryostat
sections (10–12 lm) were fixed for 10 min in cold acetone
(Sigma, Milan, Italy) at 4 C, air dried at room temperature
and stored at -20 C. Skin biopsies were also processed for
routine histology with haematoxylin/eosin (HE).
Antibodies
The following mouse anti-human antibodies were used: CD83
(HB15e, IgG1), CD86 (2331 FUN-1, IgG1) and HLA-DR
(L243, IgG2a), FITC-conjugated, from BD-Pharmingen (San
Diego, CA); BDCA-2 (AC144, IgG1), FITC-conjugated,
from Miltenyi Biotec (Bergisch Gladbach, Germany); Lang-
erin (CD207; DCGM4, IgG1) and CD1c (L161, IgG1), from
Immunotech (Marseille, France); CD1a-FITC (NA1/34,
IgG2a), from DakoCytomation (Glostrup, Denmark); MART-
1/Melan A (A103, IgG1), from Ventana Medical System, Inc.
(Tucson, AZ); CCR7 (6B3, IgG1), from MBL International
Corporation (Woburn, MA). Goat anti-mouse Alexa Fluor
594 was used as secondary antibodies and fluorescein signal
was amplified with anti FITC Alexa Fluor 488 conjugated,
both from Molecular Probes (Invitrogen, Milan, Italy). Iso-
type-matched antibodies were used as negative controls.
Immunofluorescence
Double immunofluorescence analyses were performed on
cryostat sections at room temperature unless otherwise
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indicated. Sections were pre-treated with 20 mg/ml BSA in
PBS (Sigma) for 2 h and stained first with un-conjugated
antibodies for 2 h, revealed with anti mouse Alexa Fluor
594 secondary antibodies, then with FITC-conjugated
antibodies, overnight at 4 C; fluorescein signal was
amplified with anti FITC Alexa Fluor 488 antibodies.
Nuclei were labelled with Hoechst 33342 (20 lg/mL;
Sigma). Slides were mounted with Prolong antiFade
(Invitrogen) and observed with Leica DMR HC microscope
equipped for epifluorescence (Leica Microsystems GmbH,
Wetzlar, Germany).
Image acquisition and analysis
Images were acquired at 6.64 and 0.529 lm per pixel
resolution, corresponding to 169 and 2009 original mag-
nifications respectively, using Leica DC200 microscope
digital colour camera and Leica DC Viewer software. For
each specimen, n = 5 microscopic non-consecutive fields
were acquired at 2009, examined for quantitative analyses
by two independent observers (P.D.G. and G.G.), and the
average number of positive cells was determined. Then the
mean number of positive cells from all the melanoma
samples (n = 9), at different time-points (T0, d7, d14), was
calculated. Quantitative analyses were first performed by
counting DCs defined as HLA-DR? large mononuclear
cells with dendrities, as previously described [12]. Then
quantitative analyses were performed by counting directly
the different DC subsets by using specific monoclonal
antibodies, thus Langerhans cells (LCs) were identified as
Langerin? and CD1a? cells, dermal DCs (dDCs) as CD1c?
HLADR? cells and plasmacytoid DCs (pDCs) as BDCA2?
cells.
Statistical analysis
The values reported throughout the text are expressed as
mean ± SD and represent the mean number of positive
cells from all the patients (n = 9), at different time-points
(T0, d7, d14).
Statistical evaluation was performed using two-sided
Student’s t test with p \ 0.05 adopted as the level of
significance.
Results
Clinical effects of electrochemotherapy on metastatic
melanoma lesions
In order to establish the appropriate time to take biopsies
from ECT-treated lesions, we first addressed our attention
on the clinical signs of inflammation following the
treatment. Metastatic lesions usually appeared as a well
delimited nodule either elevated on the skin surface
(Fig. 1a, upper panels) or localized in the subcutaneous
tissue (Fig. 1a lower panels, b, and c). Few hours after ECT
treatment, the lesions appeared swollen and reddish due to
an inflammatory reaction that gradually increased until d7-
14 after treatment in parallel with a marked regression of
the lesions (Fig. 1a). Both cutaneous and subcutaneous
lesions responded to ECT. Based on these clinical obser-
vations, we decided to take biopsies after seven (d7) and
14 days (d14) from treatment. The biopsies were per-
formed at the margin of the lesion to include a fragment of
metastasis and a rim of apparently healthy perilesional
tissue (Fig. 1b, c). In place of HE staining (Fig. 1b), the
different anatomical compartments were identified
throughout the study by Hoechst staining (Fig. 1c), a
nuclear fluorescent dye (blue). Metastatic cells were iden-
tified by the expression of MART-1 (Melanoma Antigen
Recognized by T-cells), a typical protein of melanocyte
lineage and used for melanoma diagnosis.
Cutaneous DC subsets within metastatic melanoma
lesion before electrochemotherapy
Before treatment (T0) Langerhans cells (LCs), detected by
the co-expression of CD1a and Langerin [13], were the
most represented skin DC subset, located in the epidermis
over the tumour mass and rarely scattered in the dermis
(Fig. 2a). Epidermal LCs expressed HLA-DR (Fig. 2b),
little amount of CD86, but not CD80 and CD83 (data not
shown), exhibiting a typical immature immunophenotype.
A distinct subpopulation of Langerin- HLA-DR? dendritic
appearing cells was also observed scattered in the upper
dermis and in peritumoural dermis (Fig. 2b, c). A further
characterization showed that most of these Langerin-
HLA-DR? cells in the dermis co-expressed the CD1c
antigen, a marker of dermal DCs (dDCs) [14] (Fig. 2d).
Few LCs were also detected within the tumour mass,
strongly positive for MART-1 (Fig. 2e). Plasmacytoid DCs
(pDCs), the lymphoid DC subset identified by the specific
expression of BDCA-2 antigen [15], were not observed
before treatment (data not shown). Thus, in metastatic
lesions, the DCs compartment at T0 is mainly represented
by epidermal LCs and, at lesser extent, by dDCs.
Epidermal langerhans cells activation
after electrochemotherapy
After treatment a significant reduction of epidermal LCs
number was observed at d7 as compared to T0
(3.01 ± 0.88 and 14.98 ± 2.41, respectively; p \ 0.001)
(Fig. 3a, c). Importantly, in some cases LCs were
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completely disappeared from the epidermis while the few
cells observed displayed a round morphology, apparently
without dendritic processes (data not shown). These data
suggested that ECT might have induced a rapid LCs
migration to the local draining LNs. In order to investigate
this issue, we took additional biopsies at d1 after ECT
(n = 3 patients) to analyse the expression of CD83, the DC
maturation marker, and CCR7, which mediates LC
migration to regional LNs [16]. Indeed at d1 after ECT
some epidermal LCs expressed CD83 (Fig. 3d) and CCR7
(Fig. 3e). Moreover, we observed a reduction in the LCs
number, as compared to T0, although not significant.
Interestingly on d14 the epidermal LCs subset, strongly
Langerin? HLA-DR? and with the typical dendritic
appearance, was almost reconstituted and similar to T0
(d14: 14.01 ± 3.19) (Fig. 3b, c).
Dermal and plasmacytoid DCs recruitment
in the perilesional dermis after electrochemotherapy
In the dermis the number of Langerin? LCs did not sig-
nificantly vary from T0 to d7 and d14 after treatment
(1.35 ± 0.49, 1.65 ± 0.89 and 1.9 ± 0.8, respectively)
(Fig. 4d). However, in line with clinical observations, the
inflammatory infiltrate in the dermis, that was modest at
T0, increased considerably after treatment (data not
shown). In particular a high number of Langerin- HLA-
DR? dendritic appearing cells infiltrated the peritumoural
Fig. 1 Skin melanoma metastatic lesions before and after ECT
treatment. a Two typical melanoma metastases; images before ECT
(T0) and 7 and 14 days after treatment (d7 and d14 post). An
exophytic cutaneous (upper panels) and subcutaneous (lower panels)
metastases are shown. b–c Representative serial frozen sections from
a subcutaneous metastasis, labelled with standard haematoxylin and
eosin (HE) (b) and with Hoechst (c), a nuclear fluorescent dye (blue),
used here as surrogate of haematoxylin nuclear staining to compare
the different tumoural and peritumoural anatomical compartments:
the epidermis, the dermis, and the metastatic nodule (MTX). Dotted
lines indicate the epidermal-dermal barrier (Original magnification
916). (Color figure online)
Clin Exp Metastasis
123
dermis at d7 and increased at d14 (Fig. 4a, b). These cells
were mainly located around the shrinking tumour mass and
they were often very close to melanoma cells (Fig. 4a, b).
We quantified the HLA-DR? dendritic appearing cells at
T0, d7 and d14 post. The mean number of HLA-DR? DCs
significantly increased from d7 (12.46 ± 1.94) to d14
(23.14 ± 5.71) as compared to T0 (8.35 ± 1.24) (p \ 0.05
and p \ 0.01, respectively) (Fig. 4c). A further immuno-
phenotype characterization of this HLA-DR? DCs popu-
lation revealed that the majority co-expressed CD1c thus
identifying these cells as dDCs (Fig. 4e, f). The number of
CD1c? dDCs significantly increased from d7 (8.34 ±
1.69) to d14 (16.11 ± 2.95) after ECT as compared to T0
(5.63 ± 1.01) (p \ 0.05 and p \ 0.001, respectively)
(Fig. 4d). On d7 and even more on d14 some of CD1c?
DCs were positive for CD83 (Fig. 4g, h), suggesting that
dDCs reached the maturation at peritumoural level.
Importantly, the inflammatory infiltrate observed in the
perilesional dermis contained the BDCA2? pDCs, a DCs
subset not detected at T0, which significantly increased
from d7 to d14 (4.37 ± 1.49 and 7.9 ± 2.58, respectively;
p \ 0.05) (Fig. 4d).
DC subsets within metastatic melanoma cells
after electrochemotherapy
At d7 pDCs were also observed within the metastatic cells
(7.5 ± 2.08) (Fig. 5a, e) and the number significantly
increased at d14 post ECT (15.66 ± 1.74, p \ 0.001),
when pDCs were typically observed in clusters around and
within the melanoma mass (Fig. 5b, e). In contrast, the few
intra-tumoural CD1a? LCs appeared reduced in number on
d7 as compared to T0 (1.25 ± 0.47 and 4.41 ± 0.9,
respectively; p \ 0.001) (Fig. 5c, e) and were not observed
at d14 after ECT (Fig. 5d, e). Notably, while expression of
MART-1 was homogeneous at T0 (Fig. 2e), it became
Fig. 3 Epidermal LCs after ECT treatment Double immunfluores-
cence analyses on frozen sections from ECT-treated melanoma
metastases (n = 9) were performed with the indicated antibodies as
described in legend for Fig. 2. Details from representative images are
shown. a Epidermal Langerin? HLA-DR?/- (orange) LCs were
reduced in number at d7 from ECT. b At d14 from ECT, LCs were
well represented within the epidermis and co-expressed Langerin and
HLA-DR (yellow/orange). c For quantitative analyses the number of
positive cells for each specimen was assessed by calculating the
average cell number counted in n = 5 different fields. Values
represent the mean number of positive cells from n = 9 melanoma
samples. Triple asterisks indicates p \ 0.001. Epidermal LCs anal-
yses show a significant reduction of LCs number at d7 from ECT and
a subsequent repopulation at d14. d–e At d1 after ECT, some
Langerin? LCs co-expressed CD83 (yellow/orange; d) and CCR7
(yellow/orange; e) within the epidermis (n = 3 patients) (Original
magnification 9200). (Color figure online)
Fig. 2 Skin DC subsets before ECT treatment Double immunoflu-
orescence analyses on frozen sections of skin melanoma metastases
(n = 9) before ECT treatment were performed with the indicated
antibodies, revealed with Alexa Fluor 594 (red) and 488 (green),
respectively. Co-expression of antigens is indicated as merge (yellow/
orange). Nuclei were labelled with Hoechst dye (blue). Details from
representative images are shown. a Langerin (red) and CD1a (green)
double staining identifies epidermal LCs (yellow/orange). b Langerin
(red) and HLA-DR (green) double staining shows co-expression on
epidermal LCs (yellow/orange); some Langerin- HLA-DR? cells
(green) are observed in the upper dermis. c The Langerin- HLA-DR?
cell population (green) is present in the peritumoural dermis, while
Langerin? HLA-DR?/- LCs (orange) are observed within the tumour
mass. d CD1c (red) and HLA-DR (green) double staining revealed
that HLA-DR? dendritic cells co-expressed CD1c (yellow/orange).
e MART-1 (red) and CD1a (green) double staining shows the
presence of CD1a? LCs within the tumour mass, characterized by
strong expression of MART-1 (Original magnification 9200). (Color
figure online)
b
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extremely variable at d7 and d14 post ECT, probably due
to the different grade and speed of tumour cell death
(Fig. 5a–d). The persistence of MART-1 expression until
d14 post ECT, despite of clinical tumour regression, indi-
cates that the source of melanoma TAA are still available
for recruited DCs.
Discussion
It has been shown that ECT induces a recruitment of
mononuclear leucocytes within and around the treated
metastatic lesions [17]. While the nature of these infiltrate
in mice has been unravelled [18], in humans it has not been
investigated. Here we show the presence of different DC
subsets in the inflammatory reaction that infiltrates ECT-
treated skin melanoma metastasis and these results were
similar in both cutaneous and subcutaneous nodules. These
findings are in line with previous data obtained in a mouse
model where it was demonstrated the recruitment of
CD11c? DCs in ECT-treated metastasis [18], although the
effects of the treatment were more rapid than in humans.
Epidermal LCs, the most represented subset before
ECT, resulted particularly affected by the treatment which
induced a considerable reduction of their number at d7 and
in some cases they almost disappeared from the epidermis.
Similarly, the few LCs observed within metastatic cells and
in the surrounding dermis were drastically reduced in
number at d7. In contrast, after 14 days, LCs normally
repopulated the epidermis, displaying their characteristic
Fig. 4 DC subsets in the dermis after ECT treatment Double
immunfluorescence analyses on frozen sections from ECT-treated
melanoma metastases (n = 9) were performed with the indicated
antibodies as described in legend for Fig. 2. Details from represen-
tative images are shown. a–b At d7 from ECT, a high number of
dermal peritumoural Langerin- HLA-DR? dendritic looking cells
(green) were observed (a), which further increased at d14 (b).
c–d Quantitative analyses were performed as described in legend for
Fig. 3; values represented the mean frequency of positive cells per
digital image. Asterisks indicates p \ 0.05; double asterisks indicates
p \ 0.01 and triple asterisks indicates p \ 0.001. c HLA-DR? cells
analyses showed a significant increase at d7 and d14 from ECT. d DC
subsets analyses in the dermis showed no significant differences in
LCs number, a significant increase of dDCs number at d7 and d14
from ECT and the appearance of pDCs at d7 that significantly
increase at d14 after treatment. e–f CD1c (red) and HLA-DR (green)
double staining revealed that HLA-DR? dendritic cells co-expressed
CD1c (yellow/orange) (e) and the number of CD1c? HLA-DR? DCs
at d14 from ECT increased (f). g–h Some CD83? cells (green) are
observed in the dermis at d7 from ECT (g), and increased at d14 (h);
some of these cells co-expressed CD1c? (yellow/orange)
(g–h) (Original magnification 9200). (Color figure online)
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dendritic morphology. These observations suggest that
ECT treatment might have stimulated LCs migration to the
draining LNs and that this process had occurred in an early
phase. To test this hypothesis we performed additional
biopsies as early as 24 h post ECT and studied DCs acti-
vation markers. Indeed at this time some epidermal LCs
expressed CD83, the classical DC maturation marker, and
CCR7, the receptor for CCL20/MIP3b chemokine, which
mediates migration to lymphatic vessels [16], in line with
the concept that migration is linked to maturation [19, 20].
Moreover, we observed a reduction in the LCs number,
although not significant, suggesting that epidermal LCs had
been activated, but most of the cells had still to migrate.
These observations are in line with previous report showing
that electroporation treatment alone is able to induce
migration of murine epidermal LCs into the medium from
cultured skin explants, after 24 and 48 h from treatment
[21]. Although we cannot rule out the possibility that some
LCs might have died after the treatment due to bleomycin
cytotoxic effects enhanced by electrical pulses, it has been
reported that ECT does not affect non-proliferating cells
[3].
The presence of a normal epidermal LCs population at
d14 is consistent with a renewal of LC pool originating
from blood precursors.
Interestingly pDCs displayed an opposite behaviour.
They were not observed at T0, but appeared in the peri-
tumoural dermis and within metastatic cells at d7, and
further increased at d14. Although pDCs are able to pro-
duce large amount of type I IFN in response to viral
infections [22], their role in cancer immunology is con-
troversial. In melanoma patients they are suspected to play
a tolerogenic role [23, 24] and, consistently, in melanoma
draining LN they express indoleamine 2-3 dioxigenase
(IDO), a potent tolerogenic enzyme [25]. However, upon
stimulation, in vitro pDCs secrete high level of type I IFN
that promote cytotoxic T cell responses and are capable to
prime melanoma specific CD8? T cells [23, 26]. Interest-
ingly, pDCs increase in several inflamed skin conditions
[24]. The presence of pDCs in the inflammatory infiltrate of
ECT-treated melanoma metastasis is a key point. These
cells express TLR7 and TLR9 therefore their presence
represents a prerequisite for the administration of TLR7
and TLR9 agonists, two potent immune stimulators [27],
after ECT.
A central role seems to be played by dDCs, which were
present at T0 as scattered CD1c? HLA-DR? cells, and
strongly increased after ECT treatment reaching the highest
concentration at d14. Of note dDCs were typically
observed around and close to the regressing metastatic
melanoma suggesting a key role in capturing TAA that are
released by tumour cells death. As already observed for
LCs, also dDCs after ECT treatment were found to express
Fig. 5 Intra-tumoural pDCs and LCs after ECT treatment Double
immunfluorescence analyses on frozen sections from ECT-treated
melanoma metastases (n = 9) were performed with the indicated
antibodies as described in legend for Fig. 2. Details from representative
images are shown. a At d7 post ECT, scattered BDCA2? pDCs (green)
were observed within the MART-1? tumour nests (red). b At d14,
BDCA2? pDCs further increased and were observed in cluster partic-
ularly within the MART-1? tumour mass. c–d CD1a? LCs (green) within
the tumour mass decreased in number at d7 (c) and disappeared at d14
from ECT (d). Note the different expression of MART-1 in panels (a–b)
compares to panels (c–d). e Quantitative analyses of DC subsets within
the tumour mass were performed as indicated in Fig. 3. Values
represented the mean frequency of positive cells per digital image. Triple
asterisks indicates p \ 0.001. DC subsets analyses showed the significant
reduction of LCs number within the tumour mass at d7 and their absence
at d14 from ECT, and the appearance of pDCs within the tumour mass at
d7 and the significant increase of pDCs number at d14 from ECT
(Original magnification 9200). (Color figure online)
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CD83, which indicates DCs maturation. These observa-
tions indicate that ECT induces an important recruitment of
dDCs at the site of the treated lesion and some of these
dDCs might undergo in situ maturation likely due to high
levels of inflammatory cytokines.
Bleomycin may play a key role in DCs recruitment and
activation observed in ECT treated lesions. Indeed, in a
mouse model, intra-tracheal administration of bleomycin
has been reported to induce an increased numbers of
mature DCs expressing CD40, CD83 and CD86 [28].
Notably, these lung DCs are considered important in sus-
taining pulmonary inflammation and fibrosis, a side effect
that can also occur in patients undergoing ECT with sys-
temic bleomycin [1, 4]. Even though bleomycin may
strongly contribute to DCs recruitment in the perilesional
tissue, this result requires some days in mice, in which
treatment effects are more rapid than in humans [18, 28].
Thus it is likely that the rapid expression of CD83 and
CCR7 that we observed on LCs at 1d post ECT, might be
due to the combination of bleomicyn and the electric
pulses.
Although the presence of a high number of DCs and
melanoma antigens in the ECT-treated lesion are important
requirements for generating anticancer immunity, the
clinical observations demonstrate that it is not sufficient.
Indeed regression of untreated distant metastases have
never been reported and ECT has shown only a local effect
[1–3]. This may be due to defective function of peri-
tumoural DCs. Indeed melanoma associated DCs have
been shown to be mediators of tumour-induced tolerance in
metastatic lesions due to immunosuppressive cytokines
[12, 26, 29, 30]. However, ECT treatment through the
massive cancer cell death and the inflammatory reaction
that follows, might alter the melanoma induced immuno-
suppressive microenvironment [4]. The presence of some
CD83? DCs supports this hypothesis, nevertheless these
DCs are still inadequate to induce a relevant response. In
contrast, the administration of immunoadjuvant, such as
TLRs agonists, which have been shown to potentiate the
level of DC activation, can enhance anti melanoma
immunity and achieve a systemic clinical response [18,
32]. In particular, the administration of TLR7 and TLR9
agonists might be important to activate recruited pDCs [27].
In conclusion the high number of DCs and the charac-
terization of the distinct DC subsets in the inflammatory
infiltrate of ECT-treated melanoma metastasis provide the
rationale for a new therapeutic approach in metastatic
melanoma patients by combining ECT treatment with in
situ DCs activation and targeting (i.e. in situ DCs vacci-
nation) [31–33]. In this way the effective local effects of
ECT might be enhanced and turned in a systemic treatment
by the activation of local recruited DCs.
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